| Literature DB >> 7550348 |
M A Kay1, A X Holterman, L Meuse, A Gown, H D Ochs, P S Linsley, C B Wilson.
Abstract
Recombinant adenovirus vectors are efficient at transferring genes into somatic tissues but are limited for use in clinical gene therapy by immunologic factors that result in the rapid loss of gene expression and inhibit secondary gene transfer. This study demonstrates that systemic coadministration of recombinant adenovirus with soluble CTLA4Ig, which is known to block co-stimulatory signals between T cells and antigen presenting cells, leads to persistent adenoviral gene expression in mice without long-term immunosuppression. This form of immunotherapy greatly enhances the likelihood that recombinant adenovirus vectors will be useful for human gene therapy.Entities:
Mesh:
Substances:
Year: 1995 PMID: 7550348 DOI: 10.1038/ng1095-191
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330